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Almost  50  years  ago  Dahlström  and 
Fuxe  discovered  serotonergic  neu-
rons  in  the  brainstem.  Much  remains 
to  learn,  however,  about  how  serotonin 
(5-  hydroxytryptamine  or  5HT)  modu-
lates  circuit  activity.  Serotonergic  neu-
rons  release  5HT  throughout  the  CNS. 
Accordingly, these cells influence breath-
ing rhythms, body temperature, heart rate, 
pain, eating, sleep, arousal, emotion, and 
cognition  to  list  a  few  (Hensler,  2006). 
When  the  5HT  system  gets  disturbed 
much can go wrong: sudden infant death 
syndrome, obesity, psychosis, depression, 
and anxiety (Audero et al., 2008; Garfield 
and Heisler, 2009; Richardson-Jones et al., 
2010).  Understanding  these  patholo-
gies and illnesses might require, in part, 
new  ways  of  manipulating  serotonergic 
cells without affecting other cell types, as 
addressed by the recent study from Weber 
et al. (2009).
Studying circuitry with genetics often 
involves putting foreign proteins, e.g. Cre 
(cyclization  recombination)  site-specific 
DNA recombinase from bacteriophage P1, 
in specific cell types (Sauer, 2002; Dymecki 
and Kim, 2007; Gong et al., 2007). The regu-
latory regions of genes expressed only in 
5HT neurons can be hijacked to put Cre in 
these cells (Scott et al., 2005; Weber et al., 
2009). For a cell type-selective manipula-
tion, a “Cre driver mouse” is mated with 
another that has a gene with recognition 
sites for Cre. These sites, termed lox (locus 
of crossover) sites, surround an important 
exon, and the target gene is designated a 
“floxed” allele. In the nuclei of those cells 
that express the Cre enzyme, the Cre cuts 
and rejoins the DNA between the lox sites, 
so that the intervening segment gets inverted 
or  removed  (Sauer,  2002;  Dymecki  and 
Kim, 20071). This makes a cell type-specific 
knockout of a gene. A difficulty, though, is 
brain development. 5HT released during 
development  influences  how  circuitries 
which govern adult behavior work (Gross 
et al., 2002; Ansorge et al., 2004). Knocking 
out the 5HT1A receptor gene in young or 
old mice gives different phenotypes (Gross 
et al., 2002); knockout during embryogen-
esis produces heightened anxiety in adults; 
but  knockout  in  adults  does  not  (Gross 
et al., 2002). Thus if we express Cre from 
a serotonergic-specific gene active during 
embryogenesis or postnatal brain develop-
ment, Cre would turn on at an earlier point 
and by destroying a floxed gene, leave an 
irreversible genetic “footprint”. This may 
prevent a correct interpretation of the adult 
phenotype. Inducible Cre activity, where we 
can turn on the Cre recombinase at defined 
ages of the mouse, is better. Hence the Weber 
et al. (2009) paper.
Weber et al. have performed a model exer-
cise in advanced transgenesis. For directing 
Cre expression specifically to serotonergic 
neurons, they took the regulatory regions of 
the tryptophan hydroxylase 2 (Tph2) gene, 
which encodes the first enzyme of the 5HT 
synthetic pathway (Weber et al., 2009). A 
bacteriophage P1-derived artificial chromo-
some (PAC), a large (177 kb) piece of mouse 
genomic DNA that contains sufficient regu-
latory regions of the tph2 gene, served as the 
expression platform. In the PAC, the tph2 
coding region was changed to produce an 
inducible Cre recombinase instead of the 
Tph2. This modified PAC was injected into 
nuclei of mouse embryos where it integrated 
randomly in the genome.
So  that  the  Cre  could  be  activated 
at  specific  times,  the  authors  used  Cre 
recombinase fused with the ligand bind-
ing region of the estrogen receptor (ER). 
The ER domain stopped Cre from cutting 
DNA. However, Cre’s activity within the 
Cre-ER protein (known as Cre-ERT2) could 
be released by the drug tamoxifen, which 
binds to the ER segment (Indra et al., 1999). 
The experimental mice were generated by 
crossing a strain with a floxed-allele (vari-
ous floxed “reporter” alleles were used by 
Weber et al., as examples) with the TPH2-
CreERT2 mice. Because Cre was inactive, 
the progeny were normal. At the chosen 
time,  tamoxifen  was  given  intraperito-
neally. Some days later, Cre recombined the 
target gene specifically in the 5HT neurons 
(Weber et al., 2009).
Weber et al’s study beautifully illustrates 
the use of inducible recombination, and the 
amount of work needed to fully characterize 
the mice (Weber et al., 2009). For this study 
the authors made their own mice; but many 
“off the shelf” Cre mouse lines are available 
(Gong et al., 2007), and more appear regularly 
(see, for example, the wonderful resource at 
GENSAT2). Ironically the GENSAT webpage 
now  lists  a  tamoxifen-inducible  Cre  line 
selective for 5HT neurons (using the Slc6a4 
gene). One needs to appreciate, however, 
that in any of the non-inducible lines Cre 
can express during development, and some-
times in different cell types from the adult. 
For this reason some non-inducible Cre lines 
are not useable. Each must be assessed to see 
when the Cre gene turns on. In conclusion, 
many neurological and psychiatric diseases 
may come from 5HT malfunctions in devel-
opment which then change the adult brain. 
The TPH2-CreERT2 mice made by Weber 
et al. (2009), and other inducible Cre mice, 
will allow investigations of when and how 
the diseases might first start, or what main-
tains them.
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